US EditionPublished • loading... • Updated
Sanofi calls rejection of potential MS blockbuster 'unexpected,' says it saw 'evolving' FDA perspectives
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Sanofi calls rejection of potential MS blockbuster 'unexpected,' says it saw 'evolving' FDA perspectives
Sanofi said the FDA’s recent rejection of its potential blockbuster MS treatment was “unexpected” and that the agency raised questions too late to make changes. The company "observed evolving perspectives within the FDA review team ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
